The Trustees of the University of Pennsylvania;The Children's Hospital of Philadelphia
发明人:
Carl H. June,Bruce L. Levine,Michael D. Kalos,Stephan Grupp
申请号：
US15972972
公开号：
US20180256712A1
申请日:
2018.05.07
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
